Light chain (AL) amyloidosis: Update on diagnosis and management

Journal of Hematology and Oncology

Volumn 4, Issue , 2011, Pages

  Rosenzweig, Michael ^a   Landau, Heather ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AMYLOID; AMYLOID PRECURSOR PROTEIN; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; POMALIDOMIDE; PREDNISONE; STEROID; THALIDOMIDE; IMMUNOGLOBULIN LIGHT CHAIN;

AMYLOIDOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BIOPSY; CYTOPENIA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTRON MICROSCOPY; FATIGUE; HUMAN; IMMUNOTHERAPY; LIGHT CHAIN; LIGHT CHAIN AMYLOIDOSIS; MUSCLE CRAMP; NEUTROPENIA; NONHUMAN; PATIENT REFERRAL; PLASMA CELL; PROGNOSIS; REVIEW; SURVIVAL; VEIN THROMBOSIS; ANIMAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METABOLISM; PARAPROTEINEMIA;

AMYLOIDOSIS; ANIMALS; DEXAMETHASONE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MELPHALAN; PARAPROTEINEMIAS;

EID: 81255128063     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-4-47     Document Type: Review

References (64)

1. Currents concepts on the immunopathology of amyloidosis. Bhat A, Selmi C, Naguwa SM, Cheema GS, Gershwin ME, Clin Rev Allergy Immunol 2010 38 97 106 10.1007/s12016-009-8163-9 19626465
2. The systemic amyloidoses. Falk RH, Comenzo RL, Skinner M, N Engl J Med 1997 337 898 909 10.1056/NEJM199709253371306 9302305 (Pubitemid 27408573)
3. "Primary" systemic amyloidosis and myeloma. Discussion of relationship and review of 81 cases. Kyle RA, Bayrd ED, Arch Intern Med 1961 107 344 53 13755566
4. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Kyle RA, Gertz MA, Semin Hematol 1995 32 45 59 7878478 (Pubitemid 24370135)
5. Systemic amyloidosis: a challenge for the rheumatologist. Perfetto F, Moggi-Pignone A, Livi R, Tempestini A, Bergesio F, Matucci-Cerinic M, Nat Rev Rheumatol 2010 6 417 29 10.1038/nrrheum.2010.84 20531382
6. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Gertz MA, Lacy MQ, Dispenzieri A, et al. Leuk Lymphoma 2010 51 2181 7 10.3109/10428194.2010.524329 20958232
7. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Comenzo RL, Zhou P, Fleisher M, Clark B, Teruya-Feldstein J, Blood 2006 107 3489 91 10.1182/blood-2005-10-4148 16439680
8. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. Lachmann HJ, Booth DR, Booth SE, et al. N Engl J Med 2002 346 1786 91 10.1056/NEJMoa013354 12050338 (Pubitemid 34586914)
9. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Arbustini E, Verga L, Concardi M, Palladini G, Obici L, Merlini G, Amyloid 2002 9 108 14 12440483 (Pubitemid 34787804)
10. The contributions of electron microscopy to the understanding and diagnosis of plasma cell dyscrasia-related renal lesions. Herrera GA, Med Electron Microsc 2001 34 1 18 10.1007/s007950100000 11479769 (Pubitemid 32744140)
11. The classification and typing of amyloid deposits. Gertz MA, Am J Clin Pathol 2004 121 787 9 10.1309/TR4LGLVRJKAMV5QT 15198347 (Pubitemid 38669269)
12. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR, Dogan A, Blood 2009 114 4957 9 10.1182/blood-2009-07-230722 19797517
13. Amyloidosis. Pepys MB, Annu Rev Med 2006 57 223 41 10.1146/annurev.med. 57.121304.131243 16409147 (Pubitemid 43261989)
14. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Gertz MA, Am J Hematol 2011 86 180 6 10.1002/ajh.21934 21264900
15. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Gertz MA, Lacy MQ, Dispenzieri A, et al. Haematologica 2007 92 1415 8 10.3324/haematol.11413 17768110 (Pubitemid 350144161)
16. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Skinner M, Sanchorawala V, Seldin DC, et al. Ann Intern Med 2004 140 85 93 14734330
17. Transplantation for amyloidosis. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Curr Opin Oncol 2007 19 136 41 10.1097/CCO.0b013e32801494c6 17272986 (Pubitemid 46204353)
18. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Gertz MA, Comenzo R, Falk RH, et al. Am J Hematol 2005 79 319 28 10.1002/ajh.20381 16044444 (Pubitemid 41098849)
19. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Dispenzieri A, Kyle R, Merlini G, et al. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2009 23 215 24 10.1038/leu.2008.307
20. Validation of the Criteria of Response to Treatment In AL Amyloidosis. Palladini G, Dispenzieri A, Gertz MAA, et al. Blood 2010 116 586 7
21. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Siragusa S, Morice W, Gertz MA, et al. Annals of hematology 2011 90 101 6 10.1007/s00277-010-1028-8 20645101
22. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Dispenzieri A, Lacy MQ, Rajkumar SV, et al. Amyloid 2003 10 257 61 10.3109/13506120309041743 14986485 (Pubitemid 38117510)
23. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. Kyle RA, Gertz MA, Greipp PR, et al. N Engl J Med 1997 336 1202 7 10.1056/ NEJM199704243361702 9110907 (Pubitemid 27183649)
24. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Comenzo RL, Vosburgh E, Simms RW, et al. Blood 1996 88 2801 6 8839879 (Pubitemid 26327537)
25. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Comenzo RL, Vosburgh E, Falk RH, et al. Blood 1998 91 3662 70 9573002 (Pubitemid 28225733)
26. Treatment of immunoglobulin light chain amyloidosis. Gertz MA, Zeldenrust SR, Curr Hematol Malig Rep 2009 4 91 8 10.1007/s11899-009-0013-6 20425420
27. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. Kumar S, Dispenzieri A, Gertz MA, N Engl J Med 2008 358 91 author reply 2-3 18175386
28. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Gertz M, Lacy M, Dispenzieri A, et al. Leuk Lymphoma 2008 49 36 41 10.1080/10428190701684518 18203009 (Pubitemid 351146880)
29. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC, Blood 2007 110 3561 3 10.1182/blood-2007-07-099481 17673601 (Pubitemid 350159622)
30. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Gertz MA, Lacy MQ, Dispenzieri A, et al. Bone marrow transplantation 2004 34 1025 31 10.1038/sj.bmt.1704691 15516945 (Pubitemid 40028833)
31. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Cohen AD, Zhou P, Chou J, et al. Br J Haematol 2007 139 224 33 10.1111/j.1365-2141.2007.06783.x 17897298 (Pubitemid 47495869)
32. Maintained Hematologic and Organ Responses at Two Years Following Stem Cell Transplant In Systemic Light-Chain Amyloidosis (AL) Using Short-Course Bortezomib and Dexamethasone Consolidation Therapy. Landau H, Hassoun H, Rosenzweig MA, et al. ASH Annual Meeting Abstracts 2010 116 2391
33. Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in patients with light-chain amyloidosis (AL). Landau HJ, Hoffman J, Hassoun H, et al. J Clin Oncol 2009 27
34. Maintained Hematologic and Organ Responses at Two Years Following Stem Cell Transplant In Systemic Light-Chain Amyloidosis (AL) Using Short-Course Bortezomib and Dexamethasone Consolidation Therapy. Landau H, Hassoun H, Rosenzweig MA, et al. Blood 2010 116 991
35. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. Jaccard A, Moreau P, Leblond V, et al. N Engl J Med 2007 357 1083 93 10.1056/NEJMoa070484 17855669 (Pubitemid 47443213)
36. Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Sanchorawala V, Wright DG, Seldin DC, et al. Br J Haematol 2002 117 886 9 10.1046/j.1365-2141.2002.03541.x 12060126 (Pubitemid 34639252)
37. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Palladini G, Anesi E, Perfetti V, et al. Br J Haematol 2001 113 1044 6 10.1046/j.1365-2141.2001.02859.x 11442500 (Pubitemid 32634774)
38. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Palladini G, Perfetti V, Obici L, et al. Blood 2004 103 2936 8 10.1182/blood-2003-08-2788 15070667 (Pubitemid 38451663)
39. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Palladini G, Russo P, Nuvolone M, et al. Blood 2007 110 787 8 10.1182/blood-2007-02-076034 17606766 (Pubitemid 47105419)
40. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Lebovic D, Hoffman J, Levine BM, et al. Br J Haematol 2008 143 369 73 10.1111/j.1365-2141.2008.07327.x 18691169
41. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Moreau P, Jaccard A, Benboubker L, et al. Blood 2010 116 4777 82 10.1182/blood-2010-07-294405 20724537
42. Melphalan and Dexamethasone Plus Bortezomib Induces Hematologic and Organ Responses in AL-Amyloidosis with Tolerable Neurotoxicity. Zonder JA, Sanchorawala V, Snyder RM, et al. Blood 2009 114 310 1 10.1182/blood-2008-12- 196287 19436053
43. Rapid haematologic and organ responses in patients with AL amyloid treated with bortezomib plus melphalan and dexamethasone. Zonder J, Sanchorawala V, Snyder R, et al. Amyloid-Journal of Protein Folding Disorders 2010 17 86 7
44. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Seldin DC, Choufani EB, Dember LM, et al. Clin Lymphoma 2003 3 241 6 10.3816/CLM.2003.n.005 12672274 (Pubitemid 36416849)
45. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Sanchorawala V, Wright DG, Rosenzweig M, et al. Blood 2007 109 492 6 10.1182/blood-2006-07-030544 16960148 (Pubitemid 46105943)
46. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2008 22 414 23
47. Pomalidomide and dexamethasone for previously treated AL: a phase 2 study. Dispenzieri A, Gertz MA, Hayman SR, et al. Amyloid-Journal of Protein Folding Disorders 2010 17 87
48. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Reece DE, Sanchorawala V, Hegenbart U, et al. Blood 2009 114 1489 97 10.1182/blood-2009-02-203398 19498019
49. High rates of overall and complete haematologic response in a prospective phase 1/2 study of weekly and twice-weekly bortezomib in relapsed AL amyloidosis. Comenzo RL, Hegenbart U, Sanchorawala V, et al. Amyloid-Journal of Protein Folding Disorders 2010 17 83 4 10.3109/13506129.2010.483118
50. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Kastritis E, Anagnostopoulos A, Roussou M, et al. Haematologica 2007 92 1351 8 10.3324/haematol.11325 18024372 (Pubitemid 350144152)
51. The Combination of Cyclophosphamide-Bortezomib-Dexamethasone (CYBOR-D) Is a Highly Effective and Well Tolerated Regimen that Produces Rapid and Complete Hematological Response In Patients with AL Amyloidosis. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. ASH Annual Meeting Abstracts 2010 116 3063
52. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Pepys MB, Herbert J, Hutchinson WL, et al. Nature 2002 417 254 9 10.1038/417254a 12015594 (Pubitemid 34534701)
53. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Gillmore JD, Tennent GA, Hutchinson WL, et al. Br J Haematol 2010 148 760 7 10.1111/j.1365-2141.2009.08036.x 20064157
54. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Pepys MB, Rademacher TW, Amatayakul-Chantler S, et al. Proc Natl Acad Sci USA 1994 91 5602 6 10.1073/pnas.91.12.5602 8202534 (Pubitemid 24174376)
55. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Bodin K, Ellmerich S, Kahan MC, et al. Nature 2010 468 93 7 10.1038/nature09494 20962779
56. Antibody-mediated resolution of light chain-associated amyloid deposits. Hrncic R, Wall J, Wolfenbarger DA, et al. Am J Pathol 2000 157 1239 46 10.1016/S0002-9440(10)64639-1 11021828
57. Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Solomon A, Weiss DT, Wall JS, Cancer Biother Radiopharm 2003 18 853 60 10.1089/108497803322702824 14969598 (Pubitemid 38064016)
58. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Jungbluth AA, Ely S, DiLiberto M, et al. Blood 2005 106 167 74 10.1182/blood-2004-12-4931 15761016 (Pubitemid 40967189)
59. Expression of cancer testis (CT) antigens in bone marrow of patients with AL amyloidosis. Rosenzweig M, Landau H, Jungbluth AA, et al. Amyloid-Journal of Protein Folding Disorders 2010 17 192
60. Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. Schonland SO, Lokhorst H, Buzyn A, et al. Blood 2006 107 2578 84 10.1182/blood-2005-06-2462 16293611 (Pubitemid 43345584)
61. Allogeneic bone marrow transplantation for systemic AL amyloidosis. Gillmore JD, Davies J, Iqbal A, Madhoo S, Russell NH, Hawkins PN, Br J Haematol 1998 100 226 8 10.1046/j.1365-2141.1998.00527.x 9450816 (Pubitemid 28051865)
62. Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high-dose melphalan. Kawai Y, Kinoshita K, Arai H, et al. Eur J Haematol 2004 72 448 50 10.1111/j.1600-0609.2004.00250.x 15128426 (Pubitemid 38703539)
63. Allogeneic bone marrow transplantation for AL amyloidosis. Guillaume B, Straetmans N, Jadoul M, Cosyns JP, Ferrant A, Bone marrow transplantation 1997 20 907 8 10.1038/sj.bmt.1700983 9404936 (Pubitemid 27493933)
64. Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis. Imamura T, Ogata M, Kohno K, et al. Am J Hematol 2006 81 281 3 10.1002/ajh.20544 16550508